Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Next Previous
Trial Profile

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acarbose (Primary) ; Benazepril (Primary) ; Candesartan cilexetil (Primary) ; Carvedilol (Primary) ; Chlortalidone (Primary) ; Diltiazem (Primary) ; Exenatide (Primary) ; Felodipine (Primary) ; Fenofibrate (Primary) ; Hydralazine (Primary) ; Hydrochlorothiazide/metoprolol (Primary) ; Lisinopril/hydrochlorothiazide (Primary) ; Metformin (Primary) ; Pioglitazone (Primary) ; Repaglinide (Primary) ; Reserpine (Primary) ; Terazosin (Primary) ; Valsartan (Primary) ; Valsartan/hydrochlorothiazide (Primary) ; ACE inhibitors; Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Alpha-glucosidase inhibitors; Amlodipine/benazepril; Angiotensin receptor antagonists; Antihyperglycaemics; Antihypertensives; Beta adrenergic receptor antagonists; Calcium channel antagonists; Cardiovascular therapies; Exenatide; Glimepiride; HMG-CoA reductase inhibitors; Insulin; Insulin aspart; Insulin detemir; Insulin glargine; Insulin suspension isophane; Insulins; Rosiglitazone; Simvastatin; Thiazide diuretics
  • Indications Alzheimer's disease; Cardiovascular disorders; Dementia; Diabetic angiopathies; Diabetic complications; Diabetic retinopathy; Hypercholesterolaemia; Hypertension; Myocardial infarction; Stroke; Type 2 diabetes mellitus; Vascular dementia
  • Focus Therapeutic Use
  • Acronyms ACCORD; ACCORD-BONE; ACCORD-BP; ACCORD-EYE; ACCORD-LIPID; ACCORD-MIND

Most Recent Events

  • 01 Sep 2024 Results evaluating the efficacy and tolerability of an intensive versus a less intensive blood glucose lowering regimen with antihyperglycaemics, in patients with type 2 diabetes mellitus at high risk of cardiovascular events published in the Endocrine.
  • 16 Sep 2023 Results of secondary analysis evaluating disparities in achieving diabetes treatment targets by race/ethnicity and educational attainment within this study, published in the Diabetologia
  • 01 Mar 2023 Results (n=10132) evaluating the longitudinal relationships between VAI and incident nephropathy outcomes in T2DM patients. published in the Diabetes/Metabolism Research and Reviews

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top